scholarly journals Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents

2020 ◽  
Vol 95 (7) ◽  
pp. 792-798
Author(s):  
Gee Youn (Geeny) Kim ◽  
Jonathan Burns ◽  
Craig W. Freyer ◽  
Keith W. Hamilton ◽  
Noelle V. Frey ◽  
...  
Keyword(s):  
High Risk ◽  
Fungal Infections ◽  
Invasive Fungal Infections ◽  
Hypomethylating Agents

scholarly journals Invasive Fungal Infections in Patients with High-Risk MDS and AML Treated with Azacitidine

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5251-5251
Author(s):  
Helena Pomares ◽  
Montserrat Arnan ◽  
Isabel Sánchez-Ortega ◽  
Anna Sureda ◽  
Rafael F. Duarte
Keyword(s):  
High Risk ◽  
Treatment Cycle ◽  
Fungal Infections ◽  
Antifungal Prophylaxis ◽  
Invasive Fungal Infections ◽  
Low Risk ◽  
Severe Neutropenia ◽  
Intensive Chemotherapy ◽  
Hypomethylating Agents ◽  
European Organization

Abstract Introduction: The incidence of invasive fungal infections (IFI) and need for antifungal prophylaxis in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia (MDS/AML) treated with hypomethylating agents is currently unknown. Methods: We retrospectively analyzed the incidence of IFI in all MDS/AML patients receiving azacitidine (75 mg/m2/day 7 days every 28-day cycle) in our center between June 2007 and June 2015. IFI diagnosis follows the European Organization for Research and Treatment of Cancer and Mycosis Study Group (EORTC/MSG) 2008 Criteria. Patients did not receive antifungal prophylaxis. Results: One hundred and twenty one consecutive unselected patients (86 MDS and 35 AML; Table 1) received a total of 948 cycles of azacitidine in this series (median 5, range 1-43). One hundred and ten (91%) received azacitidine frontline and 11 (9%) following refractoriness or relapse after previous intensive chemotherapy. Seventy one patients received ≥4 azacitidine cycles. Forty two (35 %) patients had complete medullar and cytogenetic responses. Two hundred and seventy four azacitidine cycles (28%) in 49 patients (40%) were administered during and/or led to prolonged grade IV neutropenia (<0.5x109/L ³10 days), and caused febrile neutropenia episodes in 121 cycles (12% of total, 44% of neutropenic cycles) in 45 patients (37%), range 1-6 per patient. Four IFI occurred in these patients: one possible, two probable and one proven (Table 2). The incidence of IFI was 0.42% per treatment cycle and 3.3% per patient treated for the overall series, and 0.72% per treatment cycle and 4.1% per patient treated among those with prolonged severe neutropenia. Of note, all cases of IFI occurred in either the first or the second azacitidine courses. Two patients died from IFI, leading to an IFI-related mortality rate of 1.65% per patient treated and 0.21% per treatment cycle. The numbers needed to treat with primary prophylaxis, even for an ideal agent that could potentially prevent all IFI, are well in excess of 100 courses of azacitidine and well over 20 patients throughout their treatment course, to prevent one single IFI in these patients, even among those with neutropenia. Conclusion: Our data show that patients with MDS/AML treated with azacitidine have a very low risk of IFI, including those with concurrent severe prolonged neutropenia. Primary antifungal prophylaxis should not be recommended for this subset of patients. This very low risk of IFI is a potential additional benefit from treatment of MDS/AML with hypomethylating agents, compared to conventional intensive chemotherapy. Prospective studies are needed to better address this issue. Disclosures Sureda: Takeda: Consultancy, Speakers Bureau.

Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients

2017 ◽  
Vol 99 (3) ◽  
pp. 240-248 ◽  
Author(s):  
Simone Cesaro ◽  
Gloria Tridello ◽  
Elio Castagnola ◽  
Elisabetta Calore ◽  
Francesca Carraro ◽  
...  
Keyword(s):  
Retrospective Study ◽  
High Risk ◽  
Fungal Infections ◽  
Invasive Fungal Infections ◽  
Hematological Patients

scholarly journals Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

2019 ◽  
Vol 3 (23) ◽  
pp. 4043-4049 ◽  
Author(s):  
Ibrahim Aldoss ◽  
Sanjeet Dadwal ◽  
Jianying Zhang ◽  
Bernard Tegtmeier ◽  
Matthew Mei ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Fungal Infections ◽  
Antifungal Prophylaxis ◽  
Invasive Fungal Infections ◽  
Hypomethylating Agents ◽  
Key Points ◽  
Acute Myeloid

Key Points The incidence of IFIs during VEN-HMA therapy is low, and the used antifungal prophylaxis approach did not influence the risk of IFIs. The risk of IFIs is higher in nonresponders and those who were treated in the r/r AML setting.

Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients

2009 ◽  
Vol 66 (19) ◽  
pp. 1711-1717 ◽  
Author(s):  
Joseph Menzin ◽  
Juliana L. Meyers ◽  
Mark Friedman ◽  
John R. Perfect ◽  
Amelia A. Langston ◽  
...  
Keyword(s):  
High Risk ◽  
Fungal Infections ◽  
Invasive Fungal Infections ◽  
High Risk Patients ◽  
Risk Patients ◽  
Length Of Hospitalization
Sign in / Sign up

Export Citation Format

Share Document